Results 121 to 130 of about 98,145 (299)

The best anti-HCV S/Co values for reflecting HCV infection in a university hospital in the eastern part of Turkey

Journal of Infection in Developing Countries
Introduction: The measurement of hepatitis C virus (HCV) RNA is a test that requires high cost, advanced technique, and qualified personnel. Diagnosis and treatment of patients may be delayed due to the high rate of false-positive results.
Bülent Dabanlıoğlu, Aysun Yılmaz, Sümeyye Akyüz, Barış Gülhan   +3 more
doaj   +1 more source

Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd‐EOB‐DTPA‐MRI

Hepatology Research, EarlyView.
Hepatocellular carcinoma (HCC) is a common type of liver cancer. Recently, combination therapy with atezolizumab plus bevacizumab has become a standard systemic treatment for patients with unresectable HCC. Some HCCs show high signal intensity on the hepatobiliary phase of Gd‐EOB‐DTPA–enhanced MRI.
Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, Masakatsu Tsurusaki, Keitaro Sofue, Yoshihiko Yano, Hidenori Toyoda, Atsushi Hiraoka, Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki, Norio Itokawa, Masanori Atsukawa, Kazuhito Kawata, Kazuto Tajiri, Joji Tani, Toru Ishikawa, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Takashi Kumada, Naoshi Nishida, Yuzo Kodama   +24 more
wiley   +1 more source

Antivir Ther [PDF]

Approximately 4.1 million Americans have been infected with HCV and 45-85% of chronically infected persons are unaware of their status. Rapid anti-HCV assays can assist and expedite the identification of those unaware of their infection.

core  

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Atsushi Masamune   +8 more
wiley   +1 more source

The Relationship Between Anti-HCV Screening and Clinical Features of Inpatients in Addiction Center. [PDF]

Noro Psikiyatr Ars, 2022
Karabulut S.
europepmc   +1 more source

Oral Lichen Ruber (OLR) and HCV-Infection [PDF]

, 2003
Oralni lihen ruber (OLR) je kronična, mukokutana, autoimuna bolest, još uvijek nedovoljno razjašnjene etiologije. Navode se brojni etiološki čimbenici koji se mogu odraziti i na sam patogenetski mehanizam bolesti.
Ana Cekić-Arambašin, Dolores Biočina-Lukenda, Višnja Škerk   +2 more
core   +1 more source

Updated Burden and Long‐Term Projections of Chronic Hepatitis B and C in Japan: A Nationwide Markov Modeling Study

Hepatology Research, EarlyView.
ABSTRACT Aim Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain major causes of liver‐related morbidity and mortality worldwide. Although Japan has implemented nationwide screening and treatment programs for decades, updated nationwide estimates and long‐term projections are limited.
Junko Tanaka, Akemi Kurisu, Ko Ko, Aya Sugiyama, Tomoyuki Akita   +4 more
wiley   +1 more source

PERSPECTIVES OF TREATMENT OF TERMINAL LIVER DISEASE IN CHRONIC HCV-INFECTION

Сеченовский вестник, 2010
Aim. Assessment of role of HBV viral proteins in liver disease progression in chronic HCV-infected patients.Methods. 2934 patients were included into the study, in whom serological markers of HBV- and HCV-infection were evaluated.
E. N. German, М. V. Mayevskaya, O. I. Andreytseva, V. T. Ivashkin, A. V. Chzhao   +4 more
doaj  

Seroprevalence of viral transfusion transmissible infections (HBsAg, anti-HCV, anti-HIV, Syphilis) and coinfection among healthy volunteer blood donors during 5-years in Luanda, Angola. [PDF]

Braz J Infect Dis, 2023
Quintas AE, Dias CC, Cogle ADC, Cordeiro L, Sarmento A.   +4 more
europepmc   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source